Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Re-analysis of digoxin data yields conflicting results

By News team

Debate continues over the use of digoxin in atrial fibrillation (AF). A recent suggestion that the drug’s use should be reassessed because of safety concerns is not supported by a further analysis of the same study data published online in the European Heart Journal (16 April 2013).

Last year, a post-hoc analysis of the 2002 "AF follow-up investigation of rhythm management" (AFFIRM) trial suggested that digoxin was associated with increased all-cause mortality (PJ 2012;289:654).

The latest analysis found no evidence of this. The technique of propensity-matched analysis was used to determine whether the reported association with higher mortality reflected an intrinsic adverse effect of digoxin or bias by indication (with, for example, a higher prevalence of heart failure in patients taking digoxin).

The researchers identified a cohort of around 900 pairs of patients receiving and not receiving digoxin who were balanced on key baseline characteristics. Among these matched patients, digoxin had no association with all-cause mortality (hazard ratio associated with digoxin use 1.06; 95 per cent confidence interval 0.83-1.37; P=0.64). There was also no association with all-cause admission to hospital.

The researchers say that the current analysis suggests no evidence to question the use of digoxin in AF and that the drug may be an attractive choice, especially for patients with relative contraindications to other rate-control drugs.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11120504

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Foxglove (dLochstampfer/

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.